IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10450276 B1

PDFFull Text
Date of Patent:
Oct. 22, 2019

Filed:

Aug. 22, 2016

Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto

Applicant:

Arena Pharmaceuticals, Inc., San Diego, CA (US);

Inventors:

Bradley Teegarden, San Diego, CA (US);

Dennis Chapman, San Diego, CA (US);

Marc Decaire, San Diego, CA (US);

Peter I. Dosa, San Diego, CA (US);

Konrad Feichtinger, San Diego, CA (US);

Honnappa Jayakumar, San Diego, CA (US);

Thuy-Anh Tran, San Diego, CA (US);

Sonja Strah-Pleynet, Newton, MA (US);

Jay Xu, San Diego, CA (US);

Assignee:

Arena Pharmaceuticals, Inc., San Diego, CA (US);

Attorneys:

Fish & Richardson P.C.

Lyle W. Spruce

Primary Examiner:

Kamal A Saeed

Int. Cl.
CPC ...
C07D 231/12 (2006.01); C07D 417/12 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); C07D 413/12 (2006.01); C07D 405/12 (2006.01); C07D 207/335 (2006.01); C07D 207/34 (2006.01); A61K 31/415 (2006.01);
U.S. Cl.
CPC ...
C07D 231/12 (2013.01); A61K 31/415 (2013.01); C07D 207/335 (2013.01); C07D 207/34 (2013.01); C07D 401/12 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); Y02A 50/415 (2018.01);
Abstract

The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HTserotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HTserotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.

Find Patent Forward Citations

Loading…